Gyre Therapeutics Inc
NASDAQ:GYRE 1:00:00 PM EDT
| Market Cap (Intraday) | 765.39M |
| Current PE | 65.43 |
| Forward PE | 67.75 |
| 2yr Forward PE | 6.95 |
| 10-Day MA | $7.83 |
| 50-Day MA | $8.97 |
| 200-Day MA | $10.92 |
Gyre Therapeutics Inc Stock, NASDAQ:GYRE
12770 High Bluff Drive, Suite 150, San Diego, California 92130
United States of America
Phone: +1.619.949.3681
Number of Employees: 5
Description
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.